Iter Investments

Iter Investments is a Fort Lauderdale venture firm deploying capital into early-stage companies advancing the psychedelic medicine and mental healthcare ecosystem. The mandate is broader than a strict therapeutics fund: it includes companies in pharma development, clinical infrastructure, training and provider services, and adjacent components of how psychedelic-assisted therapy will eventually be delivered at scale. Investment categories span pharma therapeutics and mental and behavioral health. Limited public information is available on a named partnership and detailed portfolio composition in conventional venture format, though the ecosystem-oriented thesis is articulated in the firm’s positioning.

Iter Investments participates at Seed and Series A with check sizes of $1M to $5M, sizing that allows the firm to be a meaningful early participant or, in some cases, lead small early rounds. The Fort Lauderdale base is unusual for life sciences investing but reflects the increasing distribution of healthcare venture activity outside coastal hubs. Geographic focus is United States-anchored given regulatory and clinical centrality, with consideration of broader markets where credible psychedelic medicine companies operate.

For founders, Iter Investments is most useful when the company touches the psychedelic medicine ecosystem in some form, whether as a therapeutics developer, a clinical service or training provider, or an enabling platform. The firm’s ecosystem orientation means founders should be ready to articulate not just their own opportunity but how it fits within the broader path to scaled psychedelic-assisted care. Diligence will weigh regulatory exposure, clinical evidence, and operating model together. Teams building general mental health digital products or unrelated biopharmaceutical programs are unlikely to be a clean fit for the mandate.